# ESMO ADVANCED COURSE PROGRAMME PANCREATIC CANCER: FROM STANDARD TREATMENT TO INDIVIDUALIZATION

# **Zurich, Switzerland** 7-8 November 2025

CO-CHAIRS Thierry Conroy, France Arndt Vogel, Germany **SPEAKERS** 

Michel Ducreux, France Angela Lamarca, Spain Teresa Macarulla, Spain Cindy Neuzillet, France Grainne O'Kane, Ireland Gerald Prager, Austria Oliver Strobel, Austria Valérie Vilgrain, France

#### **LEARNING OBJECTIVES**

- To get an updated overview of current treatment standards in pancreatic cancer discussed interactively based on patient cases, study data and guideline recommendations
- To work through the most important issues in an interdisciplinary way, and to ask the question: What do I do in my daily practice on next Monday?
- To think outside the box what could be current and future individualized therapy strategies?
- To inform individual clinical decision-making through the recommendations from ESMO Clinical Practice Guidelines

### Friday, 7 November 2025

09:00-09:10	Welcome and introduction
10'	Welcome and learning objectives introduction Thierry Conroy, FR and Arndt Vogel, DE
09:10-10:35	Session 1 – Resectable pancreatic cancer Chairs: Gerald Prager, AT and Arndt Vogel, DE
20'	Imaging, work-up, staging, and how to assess resectability Valérie Vilgrain, FR
25'	Resection and pathology; prognostic factors Oliver Strobel, AT
20'	Lessons from adjuvant therapies Thierry Conroy, FR
20'	Q&A
10:35-11:05	Coffee break

11:05-12:25	Session 2 – Neoadjuvant and induction approaches Chairs: Michel Ducreux, FR and Oliver Strobel, AT
20'	Lessons from neoadjuvant therapies: Oncological perspectives Thierry Conroy, FR
20'	'Induction therapy' for borderline resectable pancreatic cancer Gerald Prager, AT
20'	Specific surgical questions after neoadjuvant or induction therapies Oliver Strobel, AT
20'	Q&A
12:25-13:25	Lunch
13:25-14:45	Session 3 – Metastatic pancreatic cancer Chairs: Cindy Neuzillet, FR and Grainne O'Kane, IE
20'	What are the best options as first line therapy? Michel Ducreux, FR
20'	What are the best options as second line therapy? Teresa Macarulla, ES
20'	What is the best sequence? How to integrate molecular data and transcriptomic signatures in individual clinical decision Grainne O'Kane, IE
20'	Q&A
14:45-15:15	Coffee break
15:15-16:35	Session 4 – Specific situations Chairs: Thierry Conroy, FR and Angela Lamarca, ES
20'	Does personalized treatment approach by molecular profiling lead to better prognosis of metastatic pancreatic cancer? Arndt Vogel, DE
20'	Current treatment strategies for advanced pancreatic cancer in the elderly Angela Lamarca, ES
20'	Interventions for improving supportive care and quality of life in pancreatic cancer Cindy Neuzillet, FR
20'	Q&A
19:00	Networking dinner

## Saturday, 8 November 2025

09:00-12:30	Workshop sessions Three workshop sessions where clinical cases are presented by speakers with interactive questions and discussion with the audience (delegates will attend all 3 sessions on a rotation basis) 60' Workshop time
<b>Workshop 1</b> 60°	Current insights of chemotherapy for metastatic pancreatic cancer Michel Ducreux, FR and Gerald Prager, AT
<b>Workshop 2</b> 60'	How I treat locally advanced pancreatic cancer in 2025? Optimal treatment strategy? Teresa Macarulla, ES and Arndt Vogel, DE
11:00-11:30	Coffee break
Workshop 3 60'	What is the next cutting-edge treatment for pancreatic cancer? Time for precision medicine? Cindy Neuzillet, FR and Grainne O'Kane, IE
12:30-12:45	Feedback on the workshops Chairs: Michel Ducreux, FR, Teresa Macarulla, ES and Grainne O'Kane, IE
12:45-12:50	Conclusion and farewell Thierry Conroy, FR and Arndt Vogel, DE
12:50-13:50	Lunch